After hours:
| Previous Close | 10.16 |
| Open | 10.24 |
| Bid | 9.53 x 1100 |
| Ask | 9.80 x 900 |
| Day's Range | 9.16 - 10.33 |
| 52 Week Range | 6.50 - 21.66 |
| Volume | |
| Avg. Volume | 337,842 |
| Market Cap | 202.442M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.12 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 145.81 |
Business WireCybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO, November 18, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in development for the potential adjunctive treatment of major depressive disorder ("MDD"). As prev
Business WireCybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
TORONTO, November 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET.
